Prediction of Outcome and Endovascular Treatment Benefit: Validation and Update of the MR PREDICTS Decision Tool.

"Disclosures Dr Brown reports personal fees from University of Calgary during the conduct of the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) Collaboration, and personal fees from Medtronic outside the submitted work. Dr Majoie reports grants from CVON/Dutch Heart Foundation, European Commission, TWIN Foundation, and Stryker (all paid to his institution), outside the submitted work. He is a shareholder of Nico-lab, a company that focuses on the use of artificial intelligence for medical image analysis (modest). Dr Demchuk reports honoraria from Medtronic during the conduct of the HERMES Collaboration. Dr Muir reports reports personal fees and nonfinancial support from Boehringer Ingelheim, personal fees from Bayer, and personal fees from Daiichi-Sankyo, outside the submitted work. Dr Dávalos reports consultancy and advisory board fees from Medtronic Neurovascular (Steering Committee STAR); and an unrestricted grant for the REVASCAT trial (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset) from Medtronic (paid to his institution). Dr Mitchell reports speaking engagements from Stryker and Microvention and honoraria from Stryker, outside the submitted work. Dr Berkhemer has consulted for Stryker Neurovascular, and all funding was paid to his institution. Dr van Zwam reports personal fees from Stryker and Cerenovus, all paid to his institution, outside the submitted work. Dr Hill reports a research grant from Medtronic LCC paid to the University of Calgary for the HERMES Collaboration. Dr White reports grants from Microvention Terumo, Stryker, Medtronic, and Penumbra; and personal fees from Microvention Terumo, outside the submitted work. Dr Saver has acted as a scientific consultant regarding trial design and conduct for Medtronic, Stryker, Cerenovus, and Rapid Medical; reports that the University of California has patent rights in the retrieval devices for stroke. Dr Jovin has consulted for Cerenovus as DSMB/Steering Committee and Stryker Neurovascular as a principal investigator of the DAWN trial; received honoraria from Biogen as a consultant; holds stock or other ownership at Silk Road, Anaconda, Route 92, Corindus, Blockade Medical, and FreeOx Biotech. Dr Goyal reports an unrestricted research grant from Medtronic to the University of Calgary toward the HERMES collaboration; and personal fees from Medtronic, Stryker, Microvention, and Mentice, outside the submitted work. Dr van der Lugt and Dr Dippel report research grants from the Dutch Heart Foundation, the Dutch Brain Foundation, Top Sector Life Sciences & Health, the Netherlands Organisation for Health Research and Development, Stryker European Operations BV, Medtronic, Thrombolytic Science, LLC, and Cerenovus (all paid to institution), outside the submitted work."

"Sources of Funding This validation study was funded by the Erasmus MC Cost-Effectiveness Research program. The HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration was supported by an unrestricted grant from Medtronic to the University of Calgary. The MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry was partly funded by TWIN Foundation, Erasmus MC University Medical Center, Maastricht University Medical Center, and Amsterdam UMC, location AMC."